When Nvidia (NVDA) reported $30 billion in revenue in its second-quarter earnings results, the AI chipmaker disclosed that almost half of that came from only four customers. Read more…

During a recent episode of his “This Life of Mine” podcast, James Corden opened up about trying the medication for weight-loss and explained why it “didn’t really work” for him.

Semaglutide was linked to a significantly lower risk of overdose than other antidiabetic drugs in patients with type 2 diabetes and opioid use disorder. Medscape Medical News

 ​  

(MedPage Today) — This story is part of a series called “Ozempic: Weighing the Risks and Benefits.” It was produced in part through a grant from the NIHCM Foundation.
Looking at the data from clinical trials of new GLP-1 agonists, it’s clear…

(MedPage Today) — Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial suggested.
Over a 1-year follow-up, people with comorbid type 2 diabetes and opioid use disorder (OUD…

Novo Nordisk’s blockbuster drug Ozempic may offer yet another health benefit: helping to curb overdoses.Read more…

Today’s health news includes new research on Ozempic and drug overdose risk and on using MRIs to diagnose prostate cancer.

A pioneering study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.

The health benefits of blockbuster weight loss drugs are bridging the stark political divide in the United States. Read more…

“The preliminary findings from this study point to the possibility that GLP-1 medications may have value in helping to prevent opioid overdoses.” 

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear elusive, though women show greater weight reduction in general. Medscape Medical News

This cohort study uses emulation target trial methods to evaluate whether semaglutide is associated with lower rates of opioid overdose among patients with type 2 diabetes (T2D) and opioid use disorder (OUD).

1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant difference was observed between groups for cardiovascular death alone. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure, affecting patients with obesity,
The post Semaglutide reduces heart failure events in patients with preserved ejection fraction first appeared on 2 Minute Medicine. Source: 2 Minute Medicine

(MedPage Today) — Sen. Bernie Sanders (I-Vt.) on Tuesday challenged Novo Nordisk’s CEO to lower the cost of semaglutide (Ozempic, Wegovy) during a Senate Health, Education, Labor and Pensions (HELP) Committee hearing.
Sanders, the chair of the…

Increased iron levels can be dangerous for those with type 2 diabetes.

GLP1RA agonists have been increasing in popularity for treating obesity and type 2 diabetes.

The Senate Health, Education, Labor and Pension committee, led by Vermont Sen. Bernie Sanders, is hearing testimony from Novo Nordisk CEO Lars Fruergaard Jørgensen on the exhortative prices for their drugs in the U.S. CBS News’ Nancy Chen has more.

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.Read more…

Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the company’s weight-loss drugs Ozempic and Wegovy. NBC News’ Christine Romans reports on how Jørgensen claimed the high prices were due to complications of the U.S. healthcare system.

The hearing is the latest move in Sanders’ crusade to pressure drugmakers to lower their prices.

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.Read more…

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy. Here’s what to expect.

In a new push to make popular weight loss drugs more affordable, the CEO of Novo Nordisk is set to face a grilling on Capitol Hill over the high cost of Ozempic, used to treat type 2 diabetes, and Wegovy which is approved for weight loss. NBC’s Christine Romans reports for TODAY.

Recent research easing suicidality concerns about GLP-1s and suggesting potential psychiatric benefit has led to a call for further study of these drugs for mental illness. Medscape Medical News

Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify on Capitol Hill Tuesday.

Physicians fear use of weight loss drugs in teens will increase or exacerbate eating disorder cases, adding complexity to treatment. Medscape Medical News

This JAMA Data Brief discusses new data from the Medical Expenditure Panel Survey, or MEPS, Household Component, a household survey sponsored by the Agency for Healthcare Research and Quality.

Novo Nordisk’s blockbuster diabetes drug Ozempic will be eligible for U.S. government’s price negotiations in less than a year based on current criteria, the Danish… Reuters Health Information

Reuters and Getty ImagesMegyn Kelly says she misses the “fat” Oprah Winfrey of old, claiming the iconic TV host has lost her heart, “along with the pounds,” as she’s recently opted to take a weight loss drug.Kelly, the 53-year-old former Fox News anchor, told podcast listeners Friday that she finds Winfrey, 70, less trustworthy since she began taking a weight loss medication. “I miss fat Oprah, she was just genuine,” Kelly said on the The Megyn Kelly Show. “Now this thin Ozempic Oprah has lost—along with the pounds, her heart—her sense of authenticity.”Read more at The Daily Beast.